AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Interpace Biosciences, Inc.
Video analysis: IDXG
All videosNo video analysis for this stock yet. Request one from our team.
News: IDXG
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1-for-5 reverse stock split (“Reverse Stock Split”) of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on August 27, 2026, and Interpace common stock is expected to begin trading on a split-adjusted basis on the OTCID quotation system (“OTCID”) as of the commencement of market open that same day. Interpace's ticker symbol on the OTCID will temporarily change to IDXGD for a period of 20 trading days, including the effective date. The new CUSIP number for the common stock following the Reverse Stock Split will be 46062X402.
Critical Contrast: Interpace Biosciences (OTCMKTS:IDXG) versus Ethema Health (OTCMKTS:GRST)
Profitability This table compares Ethema Health and Interpace Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ethema Health -11.61% N/A -7.48% Interpace Biosciences 65.25% 219.07% 105.05% Insider and Institutional Ownership 5.7% of Interpace Biosciences shares are held by institutional investors. 55.7% of Ethema Health shares
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Q2 Revenue of $9. 1 millionQ2 Income from Continuing Operations of $0. 3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36. 1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, Aug.
